| EX0286 CANCER TARGETED GENE PANEL : LUNG WITH PDL-1 (DAKO) |
| Specimen: |
Submit formalin-fixed paraffin-embedded Tissue Block. Ship at room temperature. Tissue block must contain at least 10% tumor tissue. Provide a copy of the Histopathology report, Site of biopsy, and Clinical history. |
| Stability: |
| Room |
Refrigerated |
Frozen |
| NA |
NA |
NA |
|
| Method: |
IHC, FISH, NGS |
| Comment: |
Use test code J113 for Photomicrograph. Samples received on holidays will be reported in the next schedule / next working day. |
| Report: |
Contact us to know the TAT. |
| Usage: |
This panel aids in prognostication and therapeutic decisions for Lung carcinoma where a mutation has been demonstrated in MET, BRAF, EGFR, ERBB2, and KRAS and copy number variations in ALK1, ROS1, and MET. PD-L1 22C3 assay is indicated as a Companion Diagnostic aid in identifying patients for the treatment with KEYTRUDA (Pembrolizumab) therapy. It also enables the screening of clinically actionable targets for personalized targeted medicine in Lung adenocarcinoma. |
| Doctor Specialty: |
Oncologist |
| Disease: |
Cancer |
| Components: |
*ALK1 *ROS1 *MET amplification *MET mutation *KRAS *BRAF *ERBB2 *EGFR *PDL-1 (Dako) |
| Courier Charges: |
|
| Home Collection: |
Available (*T&C Apply) |
| Department: |
MOLECULAR DIAGNOSTICS |
| Pre Test Information: |
Provide a copy of the Histopathology report, Site of biopsy, and Clinical history. A duly filled NGS Test Requisition Form is mandatory. |
Reviews
There are no reviews yet.